Previous 10 | Next 10 |
Matinas BioPharma Holdings, Inc. (MTNB) Q3 2022 Results Conference Call November 02, 2022 04:30 PM ET Company Participants Ankit Bhargava - Investor Relations Jerry Jabbour - Chief Executive Officer Terry Matkovits - Chief Development Officer Terry Ferguson -...
Matinas Biopharma press release ( NYSE: MTNB ): Q3 GAAP EPS of -$0.03 in-line. Revenue of $1.1M beats by $0.25M . Cash, cash equivalents and marketable securities at September 30, 2022, were approximately $33.1M, compared to $49.6M at December 31, 2021. Based o...
EnACT Phase 2 study of MAT2203 in cryptococcal meningitis met its primary endpoint with 95% two-week patient survival in the Cohort 4 all-oral regimen Phase 3 pivotal trial of MAT2203 for treatment of cryptococcal meningitis to commence Q1 2023 The Infectious Diseases So...
BEDMINSTER, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform delivery tech...
Penny Stocks Under $1 Thanks to much more volatility in the stock market right now, traders are hunting for risk-on stocks. There are no more risky than penny stocks , and in this world of extremely cheap stocks, even a few pennies could mean the difference between a 5% and 50% move...
Penny Stocks Under $1 Thanks to much more volatility in the stock market right now, traders are hunting for risk-on stocks. There are no more risky than penny stocks , and in this world of extremely cheap stocks, even a few pennies could mean the difference between a 5% and 50% move...
Clinical stage biotech Matinas BioPharma Holdings ( NYSE: MTNB ) announced Friday that its experimental therapy MAT2203 met the primary endpoint for a group of patients in a Phase 2 trial for cryptococcal meningitis. MAT2203 is an oral formulation of amphotericin B based on ...
Two-week survival in Cohort 4 (all-oral regimen) was 95% in 40 patients receiving MAT2203 Mean Early Fungicidal Activity (EFA) of the rate of yeast clearance in cerebrospinal fluid exceeded the prespecified primary endpoint threshold of >0.20 CFU/mL, CSF/day Favorable...
BEDMINSTER, N.J., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announced today...
BEDMINSTER, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform delivery tech...
News, Short Squeeze, Breakout and More Instantly...
Matinas Biopharma Holdings Inc. Company Name:
MTNB Stock Symbol:
NYSE Market:
Matinas Biopharma Holdings Inc. Website:
BEDMINSTER, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces the recent successful...
BEDMINSTER, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that MAT2203, its ora...
BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces new in vitro data ...